Lercanidipin-Hcl Teva

Lercanidipine hydrochloride, the active ingredient in Lercanidipin-Hcl Teva, is a calcium channel blocker presented as a tablet for oral use. It is available in the European Union market and formulated to provide consistent bioavailability, helping to treat hypertension in adult patients by lowering elevated blood pressure.

GNH USA supplies Lercanidipin-Hcl Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to Good Distribution Practice and offers reliable logistics for global demand.

Lercanidipine is a dihydropyridine calcium‑channel blocker indicated for the management of high‑blood‑pressure conditions.

Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension. Isolated systolic hypertension: provides effective control of elevated systolic pressure, especially in older adults. Hypertension in the elderly: improves blood pressure control with a favorable tolerability profile in senior patients.

Lercanidipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warm sensation and redness, usually temporary. - Peripheral edema: swelling of ankles or lower legs. - Dizziness: sensation of light‑headedness, especially after standing. - Tachycardia: increased heart rate without other cardiac symptoms. - Palpitations: awareness of heart beating faster or irregularly.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring immediate medical attention. - Severe hypotension: marked drop in blood pressure causing faintness or shock. - Myocardial infarction: rare occurrence of heart attack symptoms. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Allergic reactions: rash, itching, or urticaria. - Stevens‑Johnson syndrome: severe skin reaction, requires urgent care.

When prescribing lercanidipine, clinicians should consider several safety precautions to minimize risk.

Blood pressure monitoring: check blood pressure regularly after initiation and dose adjustments. Hepatic impairment: use with caution in patients with moderate to severe liver disease. Elderly patients: start with low dose and titrate slowly due to increased sensitivity. Drug hypersensitivity: discontinue if signs of allergic reaction appear. Concomitant antihypertensives: monitor for additive hypotensive effects. Store at room temperature: keep in the original container, protect from moisture and light.

Lercanidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma levels and risk of hypotension. - Other calcium‑channel blockers: additive vasodilatory effect leading to excessive blood pressure drop. - Grapefruit juice: inhibits metabolism and raises drug concentration.

Moderate Interactions (Monitor Closely):\n- Diuretics: enhanced antihypertensive effect, monitor electrolytes. - Beta‑blockers: combined effect on heart rate and blood pressure, adjust dosing as needed. - ACE inhibitors or ARBs: additive blood pressure reduction, watch for symptomatic hypotension. - NSAIDs: may diminish antihypertensive efficacy, assess blood pressure control. - Antiplatelet agents: increased risk of bleeding, especially if vascular fragility is present.